Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Zydus Cadila

Zydus Cadila

A healthcare company that researches and develops various medical therapies, such as pharmaceuticals. It was founded in 1952 and is located in Gujarat, India.

Zydus Cadila is headquartered in Ahmedabad, India, and ranks 4th in the Indian pharmaceutical industry. The group has manufacturing sites and research facilities spread across five states of Gujarat, Maharashtra, Goa, Himachal Pradesh, and Sikkim in India and in the United States and Brazil.Its major areas of research include new chemical entity, biologics, and vaccines.

SARS-CoV-2 response

The company manufactures an anti-malaria drug, hydroxychloroquine (HQC). The drug is also thought to be a preventative medication for COVID-19. The United States government placed an order with the company in 2020 in order to help combat the spread of the virus throughout the country.

SARS-CoV-2 vaccine development

Zydus Cadila has reportedly fast-tracked research and development efforts into vaccine candidates for SARS-CoV-2. One of the candidates is based on a plasmid DNA platform, which is being developed by the firm's Vaccine Technology Centre in India. The research center previously developed India's first vaccine for the H1N1 "Swine Flu" epidemic n 2010.

Zydus Cadila's second SARS-CoV-2 candidate is based on an a live attenuated recombinant measles virus vectored vaccine against COVID-19. The recombinant measles virus (rMV) produced by reverse genetics would express codon-optimised proteins of the novel coronavirus and is meant induce long-term specific neutralizing antibodies, which will provide protection from the infection. The rMV vaccine candidate is being developed by Zydus Cadila's European research arm, Etna Biotech.

Timeline

May 24, 2021
Zydus Cadila launches Trastuzumab Emtansine, the first antibody drug conjugate (ADC) biosimilar and a highly effective drug for treating both early and advanced HER2 positive breast cancer, under the brand name Ujvira.
August 2020
Zydus Cadila announces that the phase-I clinical trial of its vaccine candidate ZyCoV-D is over and it has commenced phase-II clinical trials.
April 30, 2013
Zydus Cadila raises a $7,000,000 private equity from Baring Private Equity Partners India Limited.

Funding rounds

Products

Patents

Further Resources

Title
Author
Link
Type
Date

Govt places order for 10 crore hydroxychloroquine tablets with Ipca labs and Zydus Cadila

Himani Chandna

Web

April 4, 2020

Zydus Cadila On Drug To Cure COVID-19 | Dr Sharvil Patel of Zydus Cadila speaks to ET NOW

Web

March 1, 2020

Zydus Cadila, Serum Institute too in the hunt for coronavirus vaccine

PB Jayakumar

Web

April 5, 2020

News

Title
Author
Date
Publisher
Description
August 27, 2021
IndiaGlitz.com
The government's Covid panel chief NK Arora has claimed that details regarding the vaccination of children aged between 12 and 17 will be announced ahead of the Zydus Cadila
August 27, 2021
The New Indian Express
Representational Image. (File Photo | AP) By PTI NEW DELHI: The Union government is expecting Zydus Cadila's needle-free COVID-19 vaccine ZyCoV-D to be available from the first week of October. Further, a decision on whether all children or only those with co-morbidities will be administered the COVID-19 vaccine on priority has not yet been taken, the government said on Thursday. Indigenously developed Zydus Cadila's ZyCoV-D on Friday received approval for Emergency Use Authorisation from the drug regulator, making it the first vaccine in the country which would be administered in the age group of 12-18 years. On the kind of negotiations in terms of pricing and when the government plans to procure ZyCoV-D, Union Health Secretary Rajesh Bhushan said, "Coming to negotiations, what we have understood from media reports as well as our own engagement with the vaccine manufacturing company is that they would be in a position to make available this vaccine from the first week of October." "So we are in talks with them and the moment we crystallise the terms and conditions of procurement we will share it with you," he said at a press conference. On whether children with comorbidities would be prioritised for vaccination, Bhushan said whether all children should be taken up on priority or children with comorbidities should be taken up is an issue on which the standing committee on COVID-19 of NTAGI makes a recommendation. "The recommendation has not been made as yet and once it is made then the NTAGI takes a call on it and recommends it to the government and then that process is concluded and a decision is taken," he said. Covishield, Covaxin and Sputnik V vaccines are being given to only those above 18 years and unlike ZyCoV-D, which is three-dose, these are administered in two doses. The Department of Biotechnology (DBT) has said that ZyCoV-D is the world's first DNA-based vaccine against the coronavirus and when injected produces the spike protein of the SARS-CoV-2 virus and elicits an immune response, which plays a vital role in protection from the disease as well as viral clearance. It said that interim results from Phase-III clinical trials in over 28,000 volunteers showed primary efficacy of 66.6 per cent for symptomatic RT-PCR positive cases. This has been the largest vaccine trial so far in India for COVID-19, the DBT said. The vaccine had already exhibited robust immunogenicity and tolerability and safety profile in the adaptive phase one and two clinical trials. Both Phase one/two and Phase three clinical trials have been monitored by an independent data safety monitoring board, it added. ALSO WATCH |
August 27, 2021
The New Indian Express
Representational Image. (File Photo | AP) By PTI NEW DELHI: The Union government is expecting Zydus Cadila's needle-free COVID-19 vaccine ZyCoV-D to be available from the first week of October. Further, a decision on whether all children or only those with co-morbidities will be administered the COVID-19 vaccine on priority has not yet been taken, the government said on Thursday. Indigenously developed Zydus Cadila's ZyCoV-D on Friday received approval for Emergency Use Authorisation from the drug regulator, making it the first vaccine in the country which would be administered in the age group of 12-18 years. On the kind of negotiations in terms of pricing and when the government plans to procure ZyCoV-D, Union Health Secretary Rajesh Bhushan said, "Coming to negotiations, what we have understood from media reports as well as our own engagement with the vaccine manufacturing company is that they would be in a position to make available this vaccine from the first week of October." "So we are in talks with them and the moment we crystallise the terms and conditions of procurement we will share it with you," he said at a press conference. On whether children with comorbidities would be prioritised for vaccination, Bhushan said whether all children should be taken up on priority or children with comorbidities should be taken up is an issue on which the standing committee on COVID-19 of NTAGI makes a recommendation. "The recommendation has not been made as yet and once it is made then the NTAGI takes a call on it and recommends it to the government and then that process is concluded and a decision is taken," he said. Covishield, Covaxin and Sputnik V vaccines are being given to only those above 18 years and unlike ZyCoV-D, which is three-dose, these are administered in two doses. The Department of Biotechnology (DBT) has said that ZyCoV-D is the world's first DNA-based vaccine against the coronavirus and when injected produces the spike protein of the SARS-CoV-2 virus and elicits an immune response, which plays a vital role in protection from the disease as well as viral clearance. It said that interim results from Phase-III clinical trials in over 28,000 volunteers showed primary efficacy of 66.6 per cent for symptomatic RT-PCR positive cases. This has been the largest vaccine trial so far in India for COVID-19, the DBT said. The vaccine had already exhibited robust immunogenicity and tolerability and safety profile in the adaptive phase one and two clinical trials. Both Phase one/two and Phase three clinical trials have been monitored by an independent data safety monitoring board, it added. ALSO WATCH |
August 27, 2021
The New Indian Express
Representational Image. (File Photo | AP) By PTI NEW DELHI: The Union government is expecting Zydus Cadila's needle-free COVID-19 vaccine ZyCoV-D to be available from the first week of October. Further, a decision on whether all children or only those with co-morbidities will be administered the COVID-19 vaccine on priority has not yet been taken, the government said on Thursday. Indigenously developed Zydus Cadila's ZyCoV-D on Friday received approval for Emergency Use Authorisation from the drug regulator, making it the first vaccine in the country which would be administered in the age group of 12-18 years. On the kind of negotiations in terms of pricing and when the government plans to procure ZyCoV-D, Union Health Secretary Rajesh Bhushan said, "Coming to negotiations, what we have understood from media reports as well as our own engagement with the vaccine manufacturing company is that they would be in a position to make available this vaccine from the first week of October." "So we are in talks with them and the moment we crystallise the terms and conditions of procurement we will share it with you," he said at a press conference. On whether children with comorbidities would be prioritised for vaccination, Bhushan said whether all children should be taken up on priority or children with comorbidities should be taken up is an issue on which the standing committee on COVID-19 of NTAGI makes a recommendation. "The recommendation has not been made as yet and once it is made then the NTAGI takes a call on it and recommends it to the government and then that process is concluded and a decision is taken," he said. Covishield, Covaxin and Sputnik V vaccines are being given to only those above 18 years and unlike ZyCoV-D, which is three-dose, these are administered in two doses. The Department of Biotechnology (DBT) has said that ZyCoV-D is the world's first DNA-based vaccine against the coronavirus and when injected produces the spike protein of the SARS-CoV-2 virus and elicits an immune response, which plays a vital role in protection from the disease as well as viral clearance. It said that interim results from Phase-III clinical trials in over 28,000 volunteers showed primary efficacy of 66.6 per cent for symptomatic RT-PCR positive cases. This has been the largest vaccine trial so far in India for COVID-19, the DBT said. The vaccine had already exhibited robust immunogenicity and tolerability and safety profile in the adaptive phase one and two clinical trials. Both Phase one/two and Phase three clinical trials have been monitored by an independent data safety monitoring board, it added. ALSO WATCH |
August 27, 2021
The New Indian Express
Representational Image. (File Photo | AP) By PTI NEW DELHI: The Union government is expecting Zydus Cadila's needle-free COVID-19 vaccine ZyCoV-D to be available from the first week of October. Further, a decision on whether all children or only those with co-morbidities will be administered the COVID-19 vaccine on priority has not yet been taken, the government said on Thursday. Indigenously developed Zydus Cadila's ZyCoV-D on Friday received approval for Emergency Use Authorisation from the drug regulator, making it the first vaccine in the country which would be administered in the age group of 12-18 years. On the kind of negotiations in terms of pricing and when the government plans to procure ZyCoV-D, Union Health Secretary Rajesh Bhushan said, "Coming to negotiations, what we have understood from media reports as well as our own engagement with the vaccine manufacturing company is that they would be in a position to make available this vaccine from the first week of October." "So we are in talks with them and the moment we crystallise the terms and conditions of procurement we will share it with you," he said at a press conference. On whether children with comorbidities would be prioritised for vaccination, Bhushan said whether all children should be taken up on priority or children with comorbidities should be taken up is an issue on which the standing committee on COVID-19 of NTAGI makes a recommendation. "The recommendation has not been made as yet and once it is made then the NTAGI takes a call on it and recommends it to the government and then that process is concluded and a decision is taken," he said. Covishield, Covaxin and Sputnik V vaccines are being given to only those above 18 years and unlike ZyCoV-D, which is three-dose, these are administered in two doses. The Department of Biotechnology (DBT) has said that ZyCoV-D is the world's first DNA-based vaccine against the coronavirus and when injected produces the spike protein of the SARS-CoV-2 virus and elicits an immune response, which plays a vital role in protection from the disease as well as viral clearance. It said that interim results from Phase-III clinical trials in over 28,000 volunteers showed primary efficacy of 66.6 per cent for symptomatic RT-PCR positive cases. This has been the largest vaccine trial so far in India for COVID-19, the DBT said. The vaccine had already exhibited robust immunogenicity and tolerability and safety profile in the adaptive phase one and two clinical trials. Both Phase one/two and Phase three clinical trials have been monitored by an independent data safety monitoring board, it added.
SHOW MORE

References

Golden logo
By using this site, you agree to our Terms & Conditions.